Pliant Therapeutics (PLRX) Registration filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on integrin-based therapeutics targeting solid tumors and other diseases.

• Lead candidate, PLN-101095, is an oral dual selective inhibitor for solid tumors, with positive Phase 1 data in 2025.

• Proprietary drug discovery platform with a library of over 15,000 integrin-binding molecules, enabling targeted drug delivery including siRNAs.

• No approved products or product revenue; relies on external funding for ongoing operations and development.

Financial performance and metrics

• No revenue from product sales to date; financials are incorporated by reference from recent SEC filings.

• Audited financial statements for 2024 and 2025 are available and referenced in the filing.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for general corporate purposes, including R&D, clinical trials, working capital, capital expenditures, and potential acquisitions or investments.

• Management retains broad discretion over allocation of proceeds.